Sectors

AGEN
Agenus Inc.
5.70
2 x 5.70
1 x 5.71
bid
ask
+
0.12
2.15%
10:05 AM
timesize
Ytd81.53%
1y-6.86%
5.55
day range
5.84
2.71
52 week range
8.70
Open5.57Prev Close5.58Low5.55High5.84Mkt Cap232.36M
Vol312.22KAvg Vol3.93MEPS2.52P/E2.21Forward P/E-0.28
Beta1.55Short Ratio4.16Inst. Own37.10%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg3.54200-d Avg3.681yr Est8.00

AGEN News

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
businesswire.com
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer an

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in i

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
zacks.com
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer stud

Why Is Agenus Stock Falling on Tuesday?
benzinga.com
Why Is Agenus Stock Falling on Tuesday?

Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the lates

Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
zacks.com
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average

Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Semiconductor, Twin Vee, JPMorgan In Focus (UPDATED)
benzinga.com
Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Sem

U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and

Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today
benzinga.com
Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investo

ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript
seekingalpha.com
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS

Agenus shares surge as company secures up to $340M to advance colon cancer trial
proactiveinvestors.com
Agenus shares surge as company secures up to $340M to advance colon cancer trial

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session

Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump
benzinga.com
Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump

US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech d

benzinga.com
HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30

HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises

Why Is Agenus Stock Gaining Monday?
benzinga.com
Why Is Agenus Stock Gaining Monday?

Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M f

Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
benzinga.com
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN

Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-onco

Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
benzinga.com
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN

Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended it

Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
marketbeat.com
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing

Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase

US Stocks Mixed; Dow Gains Over 100 Points
benzinga.com
US Stocks Mixed; Dow Gains Over 100 Points

US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on e

Agenus shares surge as company secures up to $340M to advance colon cancer trial
proactiveinvestors.com
Agenus shares surge as company secures up to $340M to advance colon cancer trial

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke

benzinga.com
Market-Moving News for July 13th

QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline resul

VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy
proactiveinvestors.com
VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy

VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and

benzinga.com
Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Ex

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has enter

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
businesswire.com
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational RO

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

benzinga.com
Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensili

Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% thre

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
businesswire.com
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metas

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
gurufocus.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab I

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
businesswire.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio

Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves
marketbeat.com
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves

Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on

Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
zacks.com
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?

AGEN Early Access Revenues Signal a New Path Ahead of Approval
zacks.com
AGEN Early Access Revenues Signal a New Path Ahead of Approval

Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launc

Is Agenus Stock a Hold Amid Valuation and Funding Risks?
zacks.com
Is Agenus Stock a Hold Amid Valuation and Funding Risks?

AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, diluti

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
zacks.com
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early surviva

Agenus Announces Virtual 2026 Annual Shareholders Meeting
businesswire.com
Agenus Announces Virtual 2026 Annual Shareholders Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader i

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?
zacks.com
AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than A

benzinga.com
Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pre

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resiste

benzinga.com
Agenus' Noetik TARIO-2 AI Model Identifies Tumor Microenvironment Signature Predicting 64% Response

Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated

benzinga.com
Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilima

Published prospective cohort showed durable responses and manageable safety in patients with HCC fol

Earnings Scheduled For May 11, 2026
benzinga.com
Earnings Scheduled For May 11, 2026

benzinga.com
Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab,

First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal ca

Earnings Scheduled For March 16, 2026
benzinga.com
Earnings Scheduled For March 16, 2026

Earnings Scheduled For November 10, 2025
benzinga.com
Earnings Scheduled For November 10, 2025

benzinga.com
Earnings Scheduled For August 11, 2025

benzinga.com
Earnings Scheduled For May 12, 2025

benzinga.com
Earnings Scheduled For November 7, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 647 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday's session, 406 companies made new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

benzinga.com
Earnings Scheduled For May 9, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's trading, 1214 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.